Gene Therapy’s Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga.
Click Here for the full article
The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex’s innovative gene therapy drug candidate, REQORSA, shedding light on the significant impact it could potentially have in advancing the treatment of non-small cell lung cancer.
The featured video highlights the compelling story of Jacqueline Marino, a participant in the Phase 1 segment of Genprex’s Phase 1/2 Acclaim-1 clinical trial. Marino, diagnosed with non-small cell lung cancer (“NSCLC”), offers an inspiring account of her experience with REQORSA(R) Immunogene Therapy, Genprex’s flagship drug candidate, in combination with Tagrisso(R).
Marino’s narrative centers on the significant positive impact REQORSA has had on her life. Her treating physician observed that her lung cancer lesions remained stable, devoid of any signs of growth. This stability, combined with an extended period of Progression-Free Survival (“PFS”), has led to an enhanced quality of life and invaluable additional time for Marino.
REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC. The Acclaim-1 trial evaluates the safety and efficacy of combining REQORSA with Tagrisso in patients with advanced EGFR mutant NSCLC who have experienced disease progression after previous treatments.
During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment. However, the findings also have revealed promising efficacy results. One patient previously treated with standard of care therapies such as osimertinib had a partial remission (“PR”) by investigator evaluation and treatment is ongoing after 16 cycles, which is approximately 10.5 months. Another patient previously treated with osimertinib, has stable disease and treatment is ongoing after 14 cycles, or approximately 9 months. The extended and ongoing progression free survival (“PFS”) of each of these patients is significantly greater than the median PFS observed from treatment with osimertinib alone in this treatment setting in several prior clinical trials and is consistent with long-term PFS seen in prior clinical trials of REQORSA. These findings underscore the potential of REQORSA in reshaping the landscape of non-small cell lung cancer.
The release of the patient video interview on Benzinga coincides with the successful completion of the Phase 1 portion of the Acclaim-1 clinical trial. The compelling patient story, combined with the Safety Review Committee’s approval to proceed with the Phase 2 expansion segment, signify significant milestones in the development of REQORSA Immunogene Therapy.
While REQORSA is currently in early-stage clinical studies and will require successful large scale studies prior to regulatory approval and commercial availability, the patient video interview on Benzinga provides a captivating glimpse into the transformative potential of gene therapy. Marino’s journey serves as an inspirational testament to the promise of REQORSA in addressing the critical needs of NSCLC patients.
To watch Jacqueline Marino’s powerful story and delve deeper into REQORSA Immunogene Therapy, visit the featured video on Benzinga.
*It is important to note that REQORSA is an investigational drug and has not received approval from the U.S. Food and Drug Administration or any other regulatory authority. The experiences shared in the video are unique to Jacqueline Marino and may not be representative of the outcomes experienced by other patients undergoing REQORSA treatment.
For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
